Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
| Active as of 2023-12-17 |
{
"resourceType" : "Citation",
"id" : "179631",
"meta" : {
"versionId" : "1",
"lastUpdated" : "2023-11-26T22:35:32.731Z"
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: Citation</b><a name=\"179631\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Citation "179631" Version "1" Updated "2023-11-26 22:35:32+0000" </p></div><p><b>StructureDefinition Work Group</b>: cds</p><p><b>url</b>: <code>https://fevir.net/resources/Citation/179631</code></p><p><b>identifier</b>: FEvIR Object Identifier:\u00a0179631, id:\u00a019029421</p><p><b>version</b>: 1.0.0-ballot</p><p><b>title</b>: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p><p><b>status</b>: active</p><p><b>date</b>: 2023-12-17 16:55:23+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')</td><td>Medline Base <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#medline-base)</span></td></tr></table><p><b>jurisdiction</b>: World <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (m49.htm#001)</span></p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>approvalDate</b>: 2009-01-13</p><p><b>lastReviewDate</b>: 2023-02-02</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Source <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-classification-type.html\">Citation Classification Type</a>#citation-source)</span></p><p><b>classifier</b>: MEDLINE <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MEDLINE Citation Owner <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-classification-type.html\">Citation Classification Type</a>#medline-owner)</span></p><p><b>classifier</b>: National Library of Medicine, Index Section <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (elements_descriptions.html#owner_value#NLM)</span></p></blockquote><p><b>currentState</b>: Medline Citation Status of Medline <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-status-type.html\">Citation Status Type</a>#medline-medline)</span>, PubMed PublicationStatus of ppublish <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-status-type.html\">Citation Status Type</a>#pubmed-publication-status-ppublish)</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Pubmed <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-status-type.html\">Citation Status Type</a>#pubmed-pubstatus-pubmed)</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Medline <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-status-type.html\">Citation Status Type</a>#pubmed-pubstatus-medline)</span></p><p><b>period</b>: ?? --> 2009-01-14 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Entrez <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-status-type.html\">Citation Status Type</a>#pubmed-pubstatus-entrez)</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: id:\u00a019029421, id:\u00a0PMC3864402, id:\u00a010.1200/JCO.2007.15.9830, pii:\u00a0JCO.2007.15.9830</p><h3>Titles</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>Primary title <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-title-type.html\">Title Type</a>#primary)</span></td><td>English <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html\">Tags for the Identification of Languages</a>#en)</span></td><td>Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</td></tr></table><h3>Abstracts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.</td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/17237035/\">https://pubmed.ncbi.nlm.nih.gov/17237035/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a017237035</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/7679039/\">https://pubmed.ncbi.nlm.nih.gov/7679039/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a07679039</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11027418/\">https://pubmed.ncbi.nlm.nih.gov/11027418/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a011027418</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9815636/\">https://pubmed.ncbi.nlm.nih.gov/9815636/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a09815636</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10561202/\">https://pubmed.ncbi.nlm.nih.gov/10561202/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a010561202</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11134194/\">https://pubmed.ncbi.nlm.nih.gov/11134194/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a011134194</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/12610188/\">https://pubmed.ncbi.nlm.nih.gov/12610188/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a012610188</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15470214/\">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a015470214</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15470213/\">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a015470213</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/6337697/\">https://pubmed.ncbi.nlm.nih.gov/6337697/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a06337697</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/3523938/\">https://pubmed.ncbi.nlm.nih.gov/3523938/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a03523938</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/2213104/\">https://pubmed.ncbi.nlm.nih.gov/2213104/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a02213104</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9267791/\">https://pubmed.ncbi.nlm.nih.gov/9267791/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a09267791</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9123707/\">https://pubmed.ncbi.nlm.nih.gov/9123707/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a09123707</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9619712/\">https://pubmed.ncbi.nlm.nih.gov/9619712/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a09619712</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10472324/\">https://pubmed.ncbi.nlm.nih.gov/10472324/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a010472324</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10524892/\">https://pubmed.ncbi.nlm.nih.gov/10524892/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a010524892</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11256836/\">https://pubmed.ncbi.nlm.nih.gov/11256836/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a011256836</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/14706014/\">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a014706014</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/16921051/\">https://pubmed.ncbi.nlm.nih.gov/16921051/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a016921051</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/16170163/\">https://pubmed.ncbi.nlm.nih.gov/16170163/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a016170163</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10694556/\">https://pubmed.ncbi.nlm.nih.gov/10694556/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a010694556</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008</p><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18207190/\">https://pubmed.ncbi.nlm.nih.gov/18207190/</a></td></tr></table><p><b>resourceReference</b>: <span>id:\u00a018207190</span></p></blockquote><blockquote><p><b>publicationForm</b></p><h3>PublishedIns</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Identifier</b></td><td><b>Title</b></td><td><b>PublisherLocation</b></td></tr><tr><td style=\"display: none\">*</td><td>Periodical <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-published-in-type.html\">Published In Type</a>#D020492)</span></td><td>Electronic ISSN Type:\u00a01527-7755, ISOAbbreviation:\u00a0J Clin Oncol, ISSN Linking:\u00a00732-183X, Medline Title Abbreviation:\u00a0J Clin Oncol, NLM Unique ID:\u00a08309333</td><td>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</td><td>United States</td></tr></table><p><b>citedMedium</b>: Internet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-medium.html\">Cited Medium</a>#internet)</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 36</p><p><b>articleDate</b>: 2008-12-20</p><p><b>publicationDateText</b>: 2008-Dec-20</p><p><b>language</b>: English <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html\">Tags for the Identification of Languages</a>#en)</span></p><p><b>pageString</b>: 5936-42</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: Internet without issue <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-medium.html\">Cited Medium</a>#internet-without-issue)</span></p><p><b>articleDate</b>: 2008-11-24</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: Abstract <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html\">Artifact Url Classifier</a>#abstract)</span></p><p><b>url</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/19029421/\">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: DOI Based <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html\">Artifact Url Classifier</a>#doi-based)</span></p><p><b>url</b>: <a href=\"https://doi.org/10.1200/JCO.2007.15.9830\">https://doi.org/10.1200/JCO.2007.15.9830</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publishing Model <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#publishing-model)</span></p><p><b>classifier</b>: Print Electronic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#Print-Electronic)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Chemical <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#chemical)</span></p><p><b>classifier</b>: Androgen Antagonists <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000726)</span>, Antibiotics, Antineoplastic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000903)</span>, Antineoplastic Agents, Alkylating <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D018906)</span>, Antineoplastic Agents, Phytogenic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000972)</span>, Estramustine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (chemical-substances#35LT29625A; #D004961)</span>, Vinblastine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (chemical-substances#5V9KLZ54CY; #D014747)</span>, Doxorubicin <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (chemical-substances#80168379AG; #D004317)</span>, Ketoconazole <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (chemical-substances#R9400W927I; #D007654)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MeSH Heading <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading)</span></p><p><b>artifactAssessment</b>: <a name=\"meshHeading0\"> </a></p><blockquote><p/><p><a name=\"meshHeading0\"> </a></p><p><b>artifact</b>: <a href=\"#\">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Adult <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000328)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged, 80 and over <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000369)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: therapeutic use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antibiotics, Antineoplastic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000903)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Alkylating <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D018906)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Phytogenic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000972)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: therapeutic use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Doxorubicin <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D004317)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Estramustine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D004961)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Ketoconazole <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D007654)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoplasm Metastasis <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D009362)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: drug therapy <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: mortality <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Vinblastine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D014747)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publication Type <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#publication-type)</span></p><p><b>classifier</b>: Clinical Trial, Phase III <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D017428)</span>, Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D016428)</span>, Randomized Controlled Trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D016449)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Knowledge Artifact Type <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#knowledge-artifact-type)</span></p><p><b>classifier</b>: Journal Article <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html\">Citation Artifact Classifier</a>#D016428)</span></p><p><b>artifactAssessment</b>: <span>: Classifier added by Computable Publishing LLC</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Subset <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#citation-subset)</span></p><p><b>classifier</b>: IM <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (elements_descriptions.html#citationsubset#IM)</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author0\"> </a></p><blockquote><p/><p><a name=\"author0\"> </a></p><p><b>name</b>: Randall E Millikan </p></blockquote><p><b>forenameInitials</b>: RE</p><p><b>affiliation</b>: <span>: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author1\"> </a></p><blockquote><p/><p><a name=\"author1\"> </a></p><p><b>name</b>: Sijin Wen </p></blockquote><p><b>forenameInitials</b>: S</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author2\"> </a></p><blockquote><p/><p><a name=\"author2\"> </a></p><p><b>name</b>: Lance C Pagliaro </p></blockquote><p><b>forenameInitials</b>: LC</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author3\"> </a></p><blockquote><p/><p><a name=\"author3\"> </a></p><p><b>name</b>: Melissa A Brown </p></blockquote><p><b>forenameInitials</b>: MA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author4\"> </a></p><blockquote><p/><p><a name=\"author4\"> </a></p><p><b>name</b>: Brenda Moomey </p></blockquote><p><b>forenameInitials</b>: B</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author5\"> </a></p><blockquote><p/><p><a name=\"author5\"> </a></p><p><b>name</b>: Kim-Anh Do </p></blockquote><p><b>forenameInitials</b>: KA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name=\"author6\"> </a></p><blockquote><p/><p><a name=\"author6\"> </a></p><p><b>name</b>: Christopher J Logothetis </p></blockquote><p><b>forenameInitials</b>: CJ</p></blockquote></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author0</b><a name=\"author0\"> </a></p><p><b>name</b>: Randall E Millikan </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author1</b><a name=\"author1\"> </a></p><p><b>name</b>: Sijin Wen </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author2</b><a name=\"author2\"> </a></p><p><b>name</b>: Lance C Pagliaro </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author3</b><a name=\"author3\"> </a></p><p><b>name</b>: Melissa A Brown </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author4</b><a name=\"author4\"> </a></p><p><b>name</b>: Brenda Moomey </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author5</b><a name=\"author5\"> </a></p><p><b>name</b>: Kim-Anh Do </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author6</b><a name=\"author6\"> </a></p><p><b>name</b>: Christopher J Logothetis </p></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #meshHeading0</b><a name=\"meshHeading0\"> </a></p><p><b>artifact</b>: <a href=\"#\">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Adult <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000328)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged, 80 and over <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000369)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: therapeutic use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antibiotics, Antineoplastic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000903)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Alkylating <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D018906)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Phytogenic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000972)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: therapeutic use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Doxorubicin <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D004317)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Estramustine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D004961)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Ketoconazole <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D007654)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoplasm Metastasis <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D009362)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td><td>is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: drug therapy <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: mortality <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html\">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Vinblastine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#D014747)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: is not a major topic <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>classifier</b>: administration & dosage <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></div>"
},
"contained" : [
{
"resourceType" : "Practitioner",
"id" : "author0",
"name" : [
{
"family" : "Millikan",
"given" : [
"Randall E"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author1",
"name" : [
{
"family" : "Wen",
"given" : [
"Sijin"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author2",
"name" : [
{
"family" : "Pagliaro",
"given" : [
"Lance C"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author3",
"name" : [
{
"family" : "Brown",
"given" : [
"Melissa A"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author4",
"name" : [
{
"family" : "Moomey",
"given" : [
"Brenda"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author5",
"name" : [
{
"family" : "Do",
"given" : [
"Kim-Anh"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "author6",
"name" : [
{
"family" : "Logothetis",
"given" : [
"Christopher J"
]
}
]
},
{
"resourceType" : "ArtifactAssessment",
"id" : "meshHeading0",
"artifactReference" : {
"reference" : "#",
"type" : "Citation"
},
"content" : [
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000328",
"display" : "Adult",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000368",
"display" : "Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000369",
"display" : "Aged, 80 and over",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000903",
"display" : "Antibiotics, Antineoplastic",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D018906",
"display" : "Antineoplastic Agents, Alkylating",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000972",
"display" : "Antineoplastic Agents, Phytogenic",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000971",
"display" : "Antineoplastic Combined Chemotherapy Protocols",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D004317",
"display" : "Doxorubicin",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D004961",
"display" : "Estramustine",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D006801",
"display" : "Humans",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D007654",
"display" : "Ketoconazole",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D008297",
"display" : "Male",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D008875",
"display" : "Middle Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D009362",
"display" : "Neoplasm Metastasis",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D011471",
"display" : "Prostatic Neoplasms",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000188",
"display" : "drug therapy"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000401",
"display" : "mortality"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D014747",
"display" : "Vinblastine",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
}
]
}
],
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "cds"
}
],
"url" : "https://fevir.net/resources/Citation/179631",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179631",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19029421"
}
],
"version" : "1.0.0-ballot",
"title" : "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.",
"status" : "active",
"date" : "2023-12-17T16:55:23+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext" : [
{
"code" : {
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "fevir-platform-use",
"display" : "FEvIR Platform Use"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "medline-base",
"display" : "Medline Base",
"userSelected" : false
}
]
}
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate" : "2009-01-13",
"lastReviewDate" : "2023-02-02",
"author" : [
{
"name" : "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "citation-source",
"display" : "Citation Source"
}
]
},
"classifier" : [
{
"text" : "MEDLINE"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "medline-owner",
"display" : "MEDLINE Citation Owner"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code" : "NLM",
"display" : "National Library of Medicine, Index Section",
"userSelected" : false
}
]
}
]
}
],
"currentState" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "medline-medline",
"display" : "Medline Citation Status of Medline"
}
]
},
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-publication-status-ppublish",
"display" : "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate" : [
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pubmed",
"display" : "PubMed Pubstatus of Pubmed"
}
]
},
"period" : {
"end" : "2008-11-26T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-medline",
"display" : "PubMed Pubstatus of Medline"
}
]
},
"period" : {
"end" : "2009-01-14T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-entrez",
"display" : "PubMed Pubstatus of Entrez"
}
]
},
"period" : {
"end" : "2008-11-26T09:00:00.000Z"
}
}
],
"citedArtifact" : {
"identifier" : [
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19029421"
},
{
"system" : "https://www.ncbi.nlm.nih.gov/pmc/",
"value" : "PMC3864402"
},
{
"system" : "https://doi.org",
"value" : "10.1200/JCO.2007.15.9830"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "pii"
},
"value" : "JCO.2007.15.9830"
}
],
"title" : [
{
"type" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/title-type",
"code" : "primary",
"display" : "Primary title"
}
]
}
],
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
},
"text" : "Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."
}
],
"abstract" : [
{
"text" : "**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype."
}
],
"relatesTo" : [
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/17237035/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "17237035",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/7679039/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "7679039",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/11027418/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11027418",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9815636/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9815636",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10561202/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10561202",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/11134194/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11134194",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/12610188/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "12610188",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/15470214/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15470214",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/15470213/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15470213",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/6337697/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "6337697",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/3523938/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "3523938",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/2213104/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "2213104",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9267791/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9267791",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9123707/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9123707",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9619712/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9619712",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10472324/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10472324",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10524892/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10524892",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/11256836/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11256836",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/14706014/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "14706014",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"citation" : "Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993"
},
{
"type" : "cites",
"citation" : "Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979"
},
{
"type" : "cites",
"citation" : "Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982"
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/16921051/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "16921051",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/16170163/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "16170163",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10694556/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10694556",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18207190/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18207190",
"assigner" : {
"display" : "NLM"
}
}
}
}
],
"publicationForm" : [
{
"publishedIn" : {
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/published-in-type",
"code" : "D020492",
"display" : "Periodical"
}
]
},
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code" : "Electronic",
"display" : "Electronic"
}
],
"text" : "Electronic ISSN Type"
},
"system" : "https://portal.issn.org",
"value" : "1527-7755"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISOAbbreviation"
},
"system" : "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value" : "J Clin Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISSN Linking"
},
"system" : "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value" : "0732-183X"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "Medline Title Abbreviation"
},
"system" : "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value" : "J Clin Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "NLM Unique ID"
},
"system" : "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value" : "8309333"
}
],
"title" : "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
"publisherLocation" : "United States"
},
"citedMedium" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-medium",
"code" : "internet",
"display" : "Internet"
}
]
},
"volume" : "26",
"issue" : "36",
"articleDate" : "2008-12-20",
"publicationDateText" : "2008-Dec-20",
"language" : [
{
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
}
],
"pageString" : "5936-42"
},
{
"citedMedium" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-medium",
"code" : "internet-without-issue",
"display" : "Internet without issue"
}
]
},
"articleDate" : "2008-11-24"
}
],
"webLocation" : [
{
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/artifact-url-classifier",
"code" : "abstract",
"display" : "Abstract"
}
]
}
],
"url" : "https://pubmed.ncbi.nlm.nih.gov/19029421/"
},
{
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/artifact-url-classifier",
"code" : "doi-based",
"display" : "DOI Based"
}
]
}
],
"url" : "https://doi.org/10.1200/JCO.2007.15.9830"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publishing-model",
"display" : "Publishing Model",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "Print-Electronic",
"display" : "Print Electronic",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "chemical",
"display" : "Chemical",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000903",
"display" : "Antibiotics, Antineoplastic",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D018906",
"display" : "Antineoplastic Agents, Alkylating",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000972",
"display" : "Antineoplastic Agents, Phytogenic",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "35LT29625A",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D004961",
"display" : "Estramustine",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "5V9KLZ54CY",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D014747",
"display" : "Vinblastine",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "80168379AG",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D004317",
"display" : "Doxorubicin",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "R9400W927I",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D007654",
"display" : "Ketoconazole",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH Heading"
}
]
},
"artifactAssessment" : [
{
"reference" : "#meshHeading0",
"type" : "ArtifactAssessment"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publication-type",
"display" : "Publication Type"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D017428",
"display" : "Clinical Trial, Phase III",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016449",
"display" : "Randomized Controlled Trial",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "knowledge-artifact-type",
"display" : "Knowledge Artifact Type",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
}
],
"artifactAssessment" : [
{
"display" : "Classifier added by Computable Publishing LLC"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "citation-subset",
"display" : "Citation Subset",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code" : "IM",
"display" : "IM",
"userSelected" : false
}
]
}
]
}
],
"contributorship" : {
"complete" : true,
"entry" : [
{
"contributor" : {
"reference" : "#author0",
"type" : "Practitioner",
"display" : "Millikan RE"
},
"forenameInitials" : "RE",
"affiliation" : [
{
"display" : "Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org"
}
]
},
{
"contributor" : {
"reference" : "#author1",
"type" : "Practitioner",
"display" : "Wen S"
},
"forenameInitials" : "S"
},
{
"contributor" : {
"reference" : "#author2",
"type" : "Practitioner",
"display" : "Pagliaro LC"
},
"forenameInitials" : "LC"
},
{
"contributor" : {
"reference" : "#author3",
"type" : "Practitioner",
"display" : "Brown MA"
},
"forenameInitials" : "MA"
},
{
"contributor" : {
"reference" : "#author4",
"type" : "Practitioner",
"display" : "Moomey B"
},
"forenameInitials" : "B"
},
{
"contributor" : {
"reference" : "#author5",
"type" : "Practitioner",
"display" : "Do KA"
},
"forenameInitials" : "KA"
},
{
"contributor" : {
"reference" : "#author6",
"type" : "Practitioner",
"display" : "Logothetis CJ"
},
"forenameInitials" : "CJ"
}
]
}
}
}
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change